COMMUNIQUÉS West-GlobeNewswire

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
30/09/2026
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced [...]
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
30/09/2026
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- [...]
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
30/09/2026
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE [...]
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
30/09/2026
Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE [...]
Vision Alive Max by Holistic Health Labs Features MaquiBright®, the Clinically Studied Maqui Berry Extract at the Research-Matched Dose
30/09/2026
New York, USA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Holistic Health Labs has announced that Vision Alive Max , its flagship eye-nutrition formula, features MaquiBright®, the branded, standardized maqui berry extract, at [...]
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
30/09/2026
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million [...]
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
30/09/2026
REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic setting REVTORPYK [...]
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
30/09/2026
FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work AEON plans to submit an IND for CMAP [...]
Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine
30/09/2026
- Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer - - Data are consistent with [...]
Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update
30/09/2026
LONDON and PHILADELPHIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today publishes its unaudited [...]
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
30/09/2026
POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and [...]
DiFusion Activates Operating Board to Scale Therapeutic Biomaterials Platform
30/09/2026
Five-member board brings hands-on leadership in biomaterials commercialization, medical technology, spine innovation, OEM conversion and capital formation as DiFusion advances from cleared ZFUZE® devices into peptide- [...]
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
30/09/2026
– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration – WEST CHESTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Verrica [...]
Immutep Receives ~A$0.86 Million R&D Tax Incentive
30/09/2026
SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces [...]
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
30/09/2026
The highest dose group of EP-104GI (Cohort 9) demonstrated durability of symptom responses out to 52 weeks, with 66% of patients (2 of 3) maintaining clinical remission 1 The second highest dose group of EP-104GI ( [...]
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
30/09/2026
Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer Integrated regimen combines direct EUS-guided intratumoral delivery to penetrate [...]
Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards
30/09/2026
Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year WALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage [...]
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
30/09/2026
AI-enabled digital pathology analysis shows aglatimagene significantly increased lymphocyte infiltration and immune engagement with tumor cells compared to standard-of-care radiotherapy alone two years after treatment [...]
Terumo Neuro Signs Agreement to Acquire Arsenal Medical – Advancing Next-Generation Liquid Embolic Innovation for Treating Chronic Subdural Hematoma (cSDH)
30/09/2026
Proposed acquisition would add NeoCast™, an investigational technology designed for controlled delivery and predictable distal penetration, to Terumo Neuro’s neurovascular portfolio. Aliso Viejo, CA, Sept. 30, 2026 ( [...]

Pages